Further, a recent study demonstrated the therapeutic relevance of targeting mitochondrial fission factor DRP1 in BRAFV600E melanoma (51); however, it didn’t show any metabolic correlation despite a more glycolytic nature of BRAFV600E cancers (71). This evidence concerns the gene DNM1L and melanoma.